U.S. Markets open in 5 hrs 30 mins
  • S&P Futures

    3,682.25
    +28.00 (+0.77%)
     
  • Dow Futures

    29,450.00
    +165.00 (+0.56%)
     
  • Nasdaq Futures

    11,322.25
    +94.00 (+0.84%)
     
  • Russell 2000 Futures

    1,698.40
    +16.30 (+0.97%)
     
  • Crude Oil

    81.97
    +0.74 (+0.91%)
     
  • Gold

    1,679.60
    +11.00 (+0.66%)
     
  • Silver

    19.09
    +0.38 (+2.05%)
     
  • EUR/USD

    0.9836
    +0.0016 (+0.1672%)
     
  • 10-Yr Bond

    3.7470
    0.0000 (0.00%)
     
  • Vix

    31.26
    +1.08 (+3.58%)
     
  • GBP/USD

    1.1177
    +0.0053 (+0.4806%)
     
  • USD/JPY

    144.3090
    -0.1340 (-0.0928%)
     
  • BTC-USD

    19,575.47
    +231.44 (+1.20%)
     
  • CMC Crypto 200

    447.29
    +1.31 (+0.29%)
     
  • FTSE 100

    6,914.42
    +32.83 (+0.48%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Vor Bio to Participate in Upcoming Investor Conferences

·1 min read
Vor Biopharma
Vor Biopharma

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

Morgan Stanley 20th Annual Global Healthcare Conference
Fireside Chat: Monday, September 12, 2022 at 4:50 pm ET
Location: Sheraton Hotel, New York, NY

H.C. Wainwright 24th Annual Global Investment Conference (Hybrid)
Fireside chat: Wednesday, September 14, 2022 at 8:30 am ET
Location: Lotte New York Palace Hotel, New York, NY

Baird’s 2022 Global Healthcare Conference
Fireside chat: Wednesday, September 14, 2022 at 10:50 am ET
Location: Intercontinental New York Barclay, New York, NY

Jefferies Cell and Genetic Medicine Summit
Fireside chat: Friday, September 30, 2022
Location: Lotte New York Palace Hotel, New York, NY

A live webcast and archived replay of the fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference will be available on the investors section of www.vorbio.com.

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com